Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment

Clinical Cancer Research

Volumn 15, Issue 2, 2009, Pages 570-577

  Lin, Zhenhua ^a,b,c   Bazzaro, Martina ^a   Wang, Mei Cheng ^a   Chan, Kwun C ^a   Peng, Shiwen ^a   Roden, Richard B S ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b YANBIAN UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d Cancer Research Building 2 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CASPASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 6; PDZ PROTEIN; PROTEASOME; PROTEIN E6; PROTEIN E7; PROTEIN P53; TRICHOSTATIN A; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN HDLG; TUMOR SUPPRESSOR PROTEIN HMAGI; TUMOR SUPPRESSOR PROTEIN HSCRIBBLE; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CARCINOMA IN SITU; CELL DEATH; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; UTERINE CERVIX DYSPLASIA; UTERINE CERVIX EPITHELIUM; WART VIRUS;

ANIMALS; ENZYME INHIBITORS; EPITHELIUM; FEMALE; HELA CELLS; HISTONE DEACETYLASES; HUMANS; KERATINOCYTES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PROTEASOME ENDOPEPTIDASE COMPLEX; SIGNAL TRANSDUCTION; UTERINE CERVICAL NEOPLASMS;

EID: 59449084559     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1813     Document Type: Article

References (50)

1. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 2006;6:753-63.
2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
3. Hawley-Nelson P, Vousden KH, Hubbert NL, Lowy DR, Schiller JT. HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes. EMBO J 1989;8:3905-10.
4. Goodwin EC, Yang E, Lee C J, et al. Rapid induction of senescence in human cervical carcinoma cells. Proc Natl Acad Sci U S A 2000;97:10978-83.
5. Horner SM, DeFilippis RA, Manuelidis L, DiMaio D. Repression of the human papillomavirus E6 gene initiates p53-dependent, telomerase-independent senescence and apoptosis in HeLa cervical carcinoma cells. J Virol 2004;78:4063-73.
6. Johung K, Goodwin EC, DiMaio D. Human papillomavirus E7 repression in cervical carcinoma cells initiates a transcriptional cascade driven by the retinoblastoma family, resulting in senescence. J Virol 2007;81:2102-16.
7. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2:342-50.
8. Munger K, Baldwin A, Edwards KM, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;78:11451-60.
9. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
10. Huibregtse JM, Scheffner M, Howley PM. Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with p53. Mol Cell Biol 1993;13: 775-84.
11. Shai A, Pitot HC, Lambert PF. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res 2008;68: 2622-31.
12. Dyson N, Howley PM, Munger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989; 243:934-7.
13. Munger K, Werness BA, Dyson N, et al. Complex formation of human papillomavirus E7 proteins with the retinoblastoma tumor suppressor gene product. EMBO J 1989;8:4099-105.
14. Brehm A, Miska EA, McCance DJ, et al. Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 1998;391:597 -601.
15. Huh K, Zhou X, Hayakawa H, et al. Human papillomavirus type 16 E7 oncoprotein associates with the cullin 2 ubiquitin ligase complex, which contributes to degradation of the retinoblastoma tumor suppressor. J Virol 2007;81:9737-47.
16. Brehm A, Nielsen SJ, Miska EA, et al. The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth. EMBO J 1999;18: 2449-58.
17. Longworth MS, Laimins LA. The binding of histone deacetylases and the integrity of zinc finger-like motifs of the E7 protein are essential for the life cycle of human papillomavirus type 31. J Virol 2004;78: 3533-41.
18. Helt AM, Galloway DA. Destabilization of the reti noblastoma tumor suppressor by human papillomavirus type 16 E7 is not sufficient to overcome cell cycle arrest in human keratinocytes. J Virol 2001;75: 6737-47.
19. Hassig CA, Fleischer TC, Billin AN, Schreiber SL, Ayer DE. Histone deacetylase activity is required for full transcriptional repression by mSin3A. Cell 1997; 89:341-7.
20. Guenther MG, Barak O, Lazar MA. The SMRT and N-CoR corepressors are activating cofactors for histone deacetylase 3. Mol Cell Biol 2001;21:6091 -101.
21. Longworth MS, Wilson R, Laimins LA. HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs. EMBO J 2005; 24:1821 -30.
22. Finzer P, Krueger A, Stohr M, et al. HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway Oncogene 2004;23:4807-17.
23. Finzer P, Kuntzen C, Soto U, zur Hausen H, Rosl F. Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression. Oncogene 2001;20:4768-76.
24. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119: 493-501.
25. Bazzaro M, Lee MK, Zoso A, et al. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006;66:3754-63.
26. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984; 22:27-55.
27. Machado SG, Robinson GA. A direct, general approach based on isobolograms for assessing the joint action of drugs in pre-clinical experiments. Stat Med 1994;13:2289-309.
28. Massimi P, Gammoh N, Thomas M, Banks L. HPV E6 specifically targets different cellular pools of its PDZ domain-containing tumour suppressor substrates for proteasome-mediated degradation. Oncogene 2004;23:8033-9.
29. Massimi P, Shai A, Lambert P, Banks L. HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene 2008;27: 1800-4.
30. Kuballa P, Matentzoglu K, Scheffner M. The role of the ubiquitin ligase E6-AP in human papillomavirus E6-mediated degradation of PDZ domain-containing proteins. J Biol Chem 2007;282:65-71.
31. Huang BH, Laban M, Leung CH, et al. Inhibition of histone deacetylase 2 increases apoptosis and p21Cip1/WAF1 expression, independent of histone deacetylase 1. Cell Death Differ 2005;12:395-404.
32. Bazzaro M, Lin Z, Santillan A, et al. Ubiquitin pro-teasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res. In press 2008.
33. Hideshima T, Bradner JE, Wong J, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72.
34. Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66:3773-81.
35. Berkers CR, Verdoes M, Lichtman E, et al. Activity probe for in vivo profiling of the specificity of protea-some inhibitor bortezomib. Nat Methods 2005;2: 357-62.
36. Chauhan D, Catley L. Li G, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19.
37. Woodworth CD, Wang H, Simpson S, Alvarez-Salas LM, NotarioV. Overexpression of wild-type p53 alters growth and differentiation of normal human keratino-cytes but not human papillomavirus-expressing cell lines. Cell Growth Differ 1993;4:367-76.
38. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60.
39. Roccaro AM, HideshimaT, Raje N, et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 2006;66:184-91.
40. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
41. Veschini L, Belloni D, Foglieni C, et al. Hypoxiainducible transcription factor-1 á determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007;109:2565-70.
42. Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581 -9.
43. Pandey UB, Batlevi Y, Baehrecke EH, Taylor JP. HDAC6 at the intersection of autophagy, the ubiquitin-proteasome system and neurodegeneration. Autophagy 2007;3:643-5.
44. Pandey UB, Nie Z, Batlevi Y, et al. HDAC6 rescues neurodegeneration and provides an essential link between autophagy and the UPS. Nature 2007;447: 859-63.
45. Iwata A, Riley BE, Johnston JA, Kopito RR. HDAC6 and microtubules are required for autophagic degradation of aggregated huntingtin. J Biol Chem 2005; 280:40282-92.
46. Hook SS, Orian A, Cowley SM, Eisenman RN. Histone deacetylase 6 binds polyubiquitin through its zinc finger (PAZ domain) and copurifies with deubiquiti- nating enzymes. Proc Natl Acad Sci U S A 2002;99: 13425-30.
47. Kawaguchi Y, Kovacs JJ, McLaurin A, et al. The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell 2003;115:727-38.
48. Boyault C, Zhang Y Fritah S, et al. HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. Genes Dev 2007; 21:2172-81.
49. Glaser KB, Li J, Staver MJ, et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem Biophys Res Commun 2003;310: 529-36.
50. Oh M, Choi IK, Kwon HJ. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun 2008;369:1179-83.